Mimedx (MDXG) EBIT Growth (5y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.56% |
| Dec 31, 2025 | 27.05% |
| Sep 30, 2025 | 33.79% |
| Jun 30, 2025 | 32.68% |
| Mar 31, 2025 | 21.06% |
| Dec 31, 2024 | 33.68% |
| Sep 30, 2024 | -4.70% |
| Jun 30, 2024 | 27.53% |
| Mar 31, 2024 | 24.44% |
| Dec 31, 2023 | 30.14% |
| Sep 30, 2023 | 97.20% |
| Jun 30, 2023 | 45.28% |
| Mar 31, 2023 | -16.16% |
| Dec 31, 2022 | -13.96% |
| Sep 30, 2022 | -22.90% |
| Jun 30, 2022 | -27.25% |
| Mar 31, 2022 | -28.50% |
| Dec 31, 2021 | 16.49% |
| Sep 30, 2021 | -17.38% |
| Jun 30, 2021 | -16.16% |
| Mar 31, 2021 | -46.16% |
| Dec 31, 2020 | -32.45% |
| Sep 30, 2020 | -28.07% |
| Jun 30, 2020 | -24.87% |
| Mar 31, 2020 | -39.25% |
| Dec 31, 2019 | -24.96% |
| Sep 30, 2019 | 30.64% |
| Jun 30, 2019 | -112.72% |
| Mar 31, 2019 | -72.00% |
| Dec 31, 2018 | -44.65% |
| Sep 30, 2018 | 28.16% |
| Jun 30, 2018 | 33.56% |
| Mar 31, 2018 | 72.09% |
| Dec 31, 2017 | 92.83% |
| Sep 30, 2017 | 34.69% |
| Jun 30, 2017 | 129.29% |
| Mar 31, 2017 | 63.81% |
| Dec 31, 2016 | -29.43% |
| Sep 30, 2016 | 37.11% |
| Jun 30, 2016 | 28.28% |
| Mar 31, 2016 | 19.63% |